The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Indentification of a CTC-based gene expression signature predicting resistance to abiraterone and enzalutamide in mCRPC.
 
Todd Matthew Morgan
Consulting or Advisory Role - Myriad Genetics
Research Funding - GenomeDx (Inst); MDxHealth (Inst); Myriad Genetics (Inst)
 
Jae-Seung Chung
No Relationships to Disclose
 
Yugang Wang
No Relationships to Disclose
 
James Henderson
No Relationships to Disclose
 
Udit Singhal
No Relationships to Disclose
 
Yuanyuan Qiao
No Relationships to Disclose
 
Alexander Zaslavsky
No Relationships to Disclose
 
Daniel H Hovelson
No Relationships to Disclose
 
Ajjai Shivaram Alva
Consulting or Advisory Role - AstraZeneca; Eisai; Roche
Speakers' Bureau - AstraZeneca
Research Funding - Acerta Pharma (Inst); ARIAD (Inst); AstraZeneca (Inst); Bayer (Inst); BIND Biosciences (Inst); BIND Biosciences (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Genentech (Inst); Hoosier Cancer Research Network (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); United Biosource Corporation (Inst)
 
Felix Yi-Chung Feng
Leadership - PFS Genomics
Stock and Other Ownership Interests - PFS Genomics
Consulting or Advisory Role - Celgene; GenomeDx; Medivation/Astellas
Research Funding - Celgene; Varian Medical Systems
Patents, Royalties, Other Intellectual Property - I helped develop a molecular signature to predict radiation resistance in breast cancer, and this signature was patented by the University of Michigan, my employer. It is in the process of being licensed to PFS Genomics, a company that I helped found. (Inst)
 
Ganesh S. Palapattu
No Relationships to Disclose
 
Russell S. Taichman
No Relationships to Disclose
 
Arul M. Chinnaiyan
No Relationships to Disclose
 
Scott A. Tomlins
Leadership - Strata Oncology
Stock and Other Ownership Interests - Strata Oncology
Consulting or Advisory Role - Abbvie; Astellas Medivation; Janssen; Roche; Sanofi; Strata Oncology; Ventana Medical Systems
Research Funding - Astellas Medivation (Inst); Compendia Bioscience (Inst); GenomeDx (Inst); Life Technologies (Inst); Thermo Fisher Scientific (Inst)
Patents, Royalties, Other Intellectual Property - I am a coauthor on a patent issued to the University of Michigan on ETS gene fusions in prostate cancer. The diagnostic field of use has been licensed to Hologic/Gen-Probe Inc., who has sublicensed some rights to Ventana Medical Systems/Roche.
Travel, Accommodations, Expenses - Compendia Bioscience; Life Technologies; Strata Oncology; Thermo Fisher Scientific